CD74 and diffuse large B-cell lymphoma: Given the established CD74 expression at moderate-to-high levels in the majority of DLBCL, FL, and MCL biopsy samples, the totality of the in vitro, in vivo and safety data validate the potential clinical effectiveness of the CD74 targeting ADC, STRO-001.